Clinical Analysis and Survival of 83 Patients with Pulmonary Sarcomatoid Carcinoma

Abstract

1. Abstract
Pulmonary sarcomatoid carcinoma (PSC) is a rare type of lung cancer. The objective was to collect data on the clinical characteristics, EGFR mutations, KRAS mutations, tumor markers and prognosis of patients with PSC. Eighty-three patients with PSC and 83 patients with ordinary non-small cell lung cancer (NSCLC) who were treated at the Tianjin Medical University Cancer Institute and Hospital between 2008 and 2017 underwent EGFR and Kras mutation testing. We collected data on patient sex, age, smoking history, tumor size, TNM stage, immunohistochemical results, pathohistological subtype, and survival. Of the 83 PSC patients included in this study, All of the patients underwent mutations testing, Tumor markers, including Tissue Polypeptide Specific Antigen(TSPA), Squamous Cell Carcinoma antigen(SCC), Neuron Specific Enolase (NSE), and Carcinoma Embryonic Antigen (CEA). Pulmonary sarcomatoid carcinoma is more uncommon and aggressive than ordinary non-small cell lung cancer. Smoking history is a relevant factor associated with EGFR mutations in both patients with PSC and ordinary NSCLC. In patients with ordinary NSCLC, sex and subtype were relevant factors (p<0.0001). TNM stage was a prognostic factor for survival, and the tumor markers TSPA, SCC, NSE, CA199 and CEA were also prognostic factors for survival. Early detection and early diagnosis are the best methods for PSC patients. Nonsmoking PSC patients with EGFR mutations may benefit from targeted therapy, and PSC patients with low levels of tumor markers have a good prognosis.